If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
One way is to fuse modular binding sites (e.g., MS2 RNA tagging system, or RIDD-RIAD dock-and-lock system) to the phase-separating domain (e.g., synthetic RNA repeat, or IDP) that recruit "solute" or "client" of interest. Such a modular design enables engineering, optimization, and reusability of each fusion molecule, thus commonly applied in synthetic biology and metabolic engineering. Moreover, by applying a relatively slower binding system (e.g., split GFP), the recruitment of target into synthetic condensate can be fine-tuned by growth and division rates of the living cells. Another way to gain temporal control over the formation and dissolution of biomolecular condensates is by using optogenetic tools. Several different systems have been developed which allow for control of condensate formation and dissolution which rely on chimeric protein expression, and light or small molecule activation. In one system, proteins are expressed in a cell which contain light-activated oligomerization domains fused to IDRs. Upon irradiation with a specific wavelength of light, the oligomerization domains bind each other and form a 'core', which also brings multiple IDRs close together because they are fused to the oligomerization domains. The recruitment of multiple IDRs effectively creates a new biopolymer with increased valency. This increased valency allows for the IDRs to form multivalent interactions and trigger LLPS. When the activation light is stopped, the oligomerization domains disassemble, causing the dissolution of the condensate.
=== Financial operations === It is difficult to trace the financial movements of the CJNG given its multifaceted and illegal nature, but some estimate their assets to be worth over $20 billion. The main source of revenue for the cartel is the trade of illegal drugs, which is extremely profitable with markets in the United States and the EU. Money laundering through real estate investments, front businesses, cryptocurrency, and offshore financial institutes help the CJNG to disguise and distribute large sums. Key to the cartel's large revenue gains is its rapid geographic expansion; the CJNG has captured key ports of entry along the Gulf and the Pacific since its rise in 2009, increasing its ability to extract key elements of the illegal drug supply chain. Although the CJNG generates significant revenues from narco-trafficking, the takeover of non-drug related industries, which often capitalize on the expertise of local gangs who have been absorbed by the CJNG, help the cartel to create more immediate revenues and establish regional control. A variety of peripheral operations, such as extortion of tortilla, avocado, lime, and chicken industries, as well as fuel theft and counterfeit time-share dealings, help the CJNG to accumulate revenue to fund the trafficking of illegal drugs like fentanyl, cocaine, and methamphetamine into the United States. The cartel relies on the extortion of agricultural farms, recently profiting greatly off of Mexico's 'green gold', avocados.
== Synthesis == Neuropeptides are synthesized from inactive precursor proteins called prepropeptides. Prepropeptides contain sequences for a family of distinct peptides and often contain duplicated copies of the same peptides, depending on the organism. In addition to the precursor peptide sequences, prepropeptides also contain a signal peptide, spacer peptides, and cleavage sites. The signal peptide sequence guides the protein to the secretory pathway, starting at the endoplasmic reticulum. The signal peptide sequence is removed in the endoplasmic reticulum, yielding a propeptide. The propeptide travels to the Golgi apparatus where it is proteolytically cleaved and processed into multiple peptides. Peptides are packaged into dense core vesicles, where further cleaving and processing, such as C-terminal amidation, can occur. Dense core vesicles are transported throughout the neuron and can release peptides at the synaptic cleft, cell body, and along the axon. A single animal may use hundreds of different neuropeptides. In C. elegans, for example, 120 genes specify more than 250 neuropeptides.
Ascorbic acid is absorbed in the body by both active transport and passive diffusion. Approximately 70%–90% of vitamin C is active-transport absorbed when intakes of 30–180 mg/day from a combination of food sources and moderate-dose dietary supplements such as a multi-vitamin/mineral product are consumed. However, when large amounts are consumed, such as a vitamin C dietary supplement, the active transport system becomes saturated, and while the total amount being absorbed continues to increase with dose, absorption efficiency falls to less than 50%. Active transport is managed by Sodium-Ascorbate Co-Transporter proteins (SVCTs) and Hexose Transporter proteins (GLUTs). SVCT1 and SVCT2 import ascorbate across plasma membranes. The Hexose Transporter proteins GLUT1, GLUT3 and GLUT4 transfer only the oxydized dehydroascorbic acid (DHA) form of vitamin C. The amount of DHA found in plasma and tissues under normal conditions is low, as cells rapidly reduce DHA to ascorbate. SVCTs are the predominant system for vitamin C transport within the body. In both vitamin C synthesizers (example: rat) and non-synthesizers (example: human) cells maintain ascorbic acid concentrations much higher than the approximately 50 micromoles/liter (μmol/L) found in plasma. For example, the ascorbic acid content of pituitary and adrenal glands can exceed 2,000 μmol/L, and muscle is at 200–300 μmol/L. The known coenzymatic functions of ascorbic acid do not require such high concentrations, so there may be other, as yet unknown functions.
Sources: en.wikipedia.org
== Chemistry == Isavuconazonium comprises an N-(3-acetoxypropyl)-N-methylamino-carboxymethyl group linked through an ester moiety to the triazole nitrogen in isavuconazole. In the aquatic media of the body, the isavuconazole molecule is transformed into monohydrate.
"The signing of the Protocol of Rio de Janeiro in January 1942 was processed in the consciousness of the urban masses -stricto sensu-, not only as a historical fact of territorial confinement, but as a psychic and physical mutilation also assumed in individual terms. The painful saying that for decades has been repeated in school classrooms would already say: "Yellow, blue and red: the flag of the patojo." From 1941, being Ecuadorian would imply being handicapped and a loser, which will deepen the identity conflict of the Ecuadorian mestizo: if before he was incomplete, imperfect or chulla because he fled from his roots, now he was incomplete or patojo because he was facing reality." In addition, Peruvian historians, such as Germán Leguía and Martínez, have accused Ecuadorian historians of a well-documented and marked anti-Peruvianism when trying to minimize the role of the pro-Peruvian party in Guayaquil, headed by Gregorio Escobedo, during the Independence of Ecuador. Between Them would be included Pio Jaramillo Alvarado, Óscar Efrén Reyes (who would criticize the Peruvians of Saraguro, Cuenca, Loja and Guayaquil, provinces with populations that sought to annex Peru at the beginning of the 21st century, as hindrances to the national unification of Ecuador in Gran Colombia of Bolívar) and Pedro Fermín Cevallos.
Separate hard lumps, like nuts (hard to pass) Sausage-shaped but lumpy Like a sausage but with cracks on the surface Like a sausage or snake, smooth and soft Soft blobs with clear-cut edges Fluffy pieces with ragged edges, a mushy stool Watery, no solid pieces. Entirely liquid Types 1 and 2 indicate constipation. Types 3 and 4 are optimal, especially the latter, as these are the easiest to pass. Types 5–7 are associated with increasing tendency to diarrhea or urgency. Meconium is a newborn infant's first feces.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.